Michael H. Davidson to Rhabdomyolysis
This is a "connection" page, showing publications Michael H. Davidson has written about Rhabdomyolysis.
Connection Strength
2.088
-
The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter? Prog Cardiovasc Dis. 2016 Sep - Oct; 59(2):145-152.
Score: 0.571
-
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol. 2013 Mar-Apr; 7(2):102-8.
Score: 0.430
-
Safety considerations with fibrate therapy. Am J Cardiol. 2007 Mar 19; 99(6A):3C-18C.
Score: 0.293
-
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005 Jan 01; 95(1):120-2.
Score: 0.256
-
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf. 2004 Nov; 3(6):547-57.
Score: 0.253
-
Controversy surrounding the safety of cerivastatin. Expert Opin Drug Saf. 2002 Sep; 1(3):207-12.
Score: 0.218
-
Pharmacokinetic interactions between statins and fibrates. Am J Cardiol. 2005 Nov 07; 96(9A):44K-49K; discussion 34K-35K.
Score: 0.068